Treatment of Progressive Systemic Sclerosis (Scleroderma, PSS) with a New Drug Influencing Connective Tissue

Publisher Website
Google Scholar
Abstract
Cyclofenil is a new diphenyl ethylene derivative related to stilbestrol without estrogenicity but with marked effects on connective tissue metabolism. The drug was tested, 200 mg 3 times/day, in 6 patients with progressive systemic sclerosis (PSS) to analyze the expected beneficial effects on the PSS symptoms. The typical skin hardness, joint and muscle rigidity and reduced breathing capacity were improved to varying degrees. The only side-effect was a slight transient liver enzyme elevation in 1 out of 6 patients. A slight increase was found in urinary Ca and hydroxyproline excretion. In several cases serum Ca, cholesterol, triglyceride and in some cases the serum uric acid levels were decreased. The ANF [antinuclear factor] titers diminished to varying degrees in 4 out of 6 patients. Further detailed clinical and laboratory studies on the therapeutic potential of cyclofenil in PSS and other diseases affecting connective tissue seem to be justified.